



**Fig. 5.6** **a** and **b** Different poses of Remdesivir and RNA-dependent RNA polymerase docking at energy  $-276.31$

## References

1. Serafin MB et al (2020) Drug repositioning is an alternative for the treatment of coronavirus COVID-19. *Int J Antimicrob Agents* Jun 2020; 55(6):105969. <https://doi.org/10.1016/j.ijantimicag.2020.105969> Epub 2020 Apr 9
2. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, Zaslavsky L, Zhang J, Bolton EE (2019) PubChem 2019 update: improved access to chemical data. *Nucleic Acids Res* 47(D1):D1102–D1109. <https://doi.org/10.1093/nar/gky1033>
3. Hastings J, de Matos P, Dekker A et al (2013) The ChEBI reference database and ontology for biologically relevant chemistry: enhancements for 2013. *Nucleic Acids Res* 41(Database issue):D456–D463. <https://doi.org/10.1093/nar/gks1146>
4. Gordon CJ et al (2020) The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. *JBC Papers in Press*.